U.S. Markets close in 3 hrs 59 mins

Isleworth Healthcare Acquisition Corp. (ISLE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
9.99+0.00 (+0.02%)
As of 11:08AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close9.99
Bid9.98 x 36100
Ask10.00 x 2200
Day's Range9.99 - 10.00
52 Week Range9.66 - 10.00
Avg. Volume52,222
Market Cap261.697M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • American City Business Journals

    St. Pete SPAC calls off merger agreement

    A St. Petersburg-based special purpose acquisition company is terminating a merger agreement two months after inking the deal. Isleworth Healthcare Acquisition Corp. (Nasdaq: ISLE) and Aventura-based Cytovia Holdings Inc. agreed to the mutual termination agreement on June 30 after both companies’ boards of directors determined the merger would not be in stockholders’ best interests, according to documents filed with the U.S. Securities and Exchange Commission. SPAC mergers have been upended by market turmoil, with at least four deals falling through within a 24-hour period at the start of the month as the S&P 500 slipped into bear market territory for the first time since March 2020, according to Bloomberg SPAC Research.

  • PR Newswire


    Isleworth Healthcare Acquisition Corporation (Nasdaq: ISLE)("Isleworth"), a special purpose acquisition company, today announced that it has entered into an agreement with Cytovia Holdings, Inc. ("Cytovia"), a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies (the "Termination Agreement") to terminate its previously announced Merger Agreement with Cytovia, which was executed in April 2022. The Termination Agr

  • PR Newswire

    Cytovia Therapeutics presents antitumor activity of its CD38-Targeting Flex-NK™ Cell Engager antibody at EHA 2022 Congress

    Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies, announced today that the novel data it is presenting at the European Hematology Association's annual congress in Vienna, Austria on June 10th, 2022 is now available on both the EHA and Cytovia websites.